Teva Pharmaceutical Industries Revenue and Competitors

North Wales, PA USA

Location

N/A

Total Funding

Pharma

Industry

Estimated Revenue & Valuation

  • Teva Pharmaceutical Industries's estimated annual revenue is currently $16.2B per year.(i)
  • Teva Pharmaceutical Industries's estimated revenue per employee is $483,251
  • Teva Pharmaceutical Industries's current valuation is $10.1B. (January 2022)

Employee Data

  • Teva Pharmaceutical Industries has 33585 Employees.(i)
  • Teva Pharmaceutical Industries grew their employee count by 5% last year.

Teva Pharmaceutical Industries's People

NameTitleEmail/Phone
1
VPReveal Email/Phone
2
Assistant to VP, General Manager Teva IsraelReveal Email/Phone
3
Asistente GM y VP LatinoamericaReveal Email/Phone
4
CFO ScandinaviaReveal Email/Phone
5
Global VP Biosimilar Regulatory AffairsReveal Email/Phone
6
Executive Assistant to the VP NA Commercial ITReveal Email/Phone
7
CFO - Gerente FinancieroReveal Email/Phone
8
Sr VP, Global Head Regulatory AffairsReveal Email/Phone
9
Chief Staff / Global Head Regulatory Planning, Metrics, Reporting and ComplianceReveal Email/Phone
10
Executive Assistant to the VP Regulatory Affairs, US GenericsReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$43.2M2156%N/AN/A
#2
$81.8M40710%N/AN/A
#3
$11.7M580%N/AN/A
#4
$1011.8M5034-9%N/AN/A
#5
$44.8M2231%N/AN/A
#6
$13.1M655%N/AN/A
#7
$16.5M8241%N/AN/A
#8
$17.3M86-5%N/AN/A
#9
$67.9M33823%N/AN/A
#10
$14.9M747%N/AN/A
Add Company

What Is Teva Pharmaceutical Industries?

Teva is a global generic pharmaceuticals leader and one of the top 15 pharmaceutical companies in the world. Headquartered in Israel, Teva operates in 60 countries and has 45,000 employees worldwide. Established in 1901, Teva takes great pride in its long tradition of leadership and dedication to excellence. Teva specializes in development, production and marketing of a wide range of generic and branded products, as well as active pharmaceutical ingredients (API). For over a century, Teva has maintained a distinct competitive edge through: High quality offerings Focus on customers and patients Balanced product portfolio (both generic and innovative) Integration of pharmaceutical and API activities Combination of global operations with local customer responsiveness Established international presence through a tailored network of worldwide subsidiaries Teva's business is wide and diverse, yet operations are simple and lean. This allows us to maintain leadership and always keep a competitive edge. We specialize in the development, production and marketing of generic and proprietary branded products. Our portfolio covers all major therapeutic areas and a wide variety of dosage forms. We additionally produce and supply active pharmaceutical ingredients (API) to the drug manufacturing industry worldwide.

keywords:N/A

N/A

Total Funding

33585

Number of Employees

$16.2B

Revenue (est)

5%

Employee Growth %

$10.1B

Valuation

N/A

Accelerator

Teva Pharmaceutical Industries News

2022-04-17 - Teva Pharmaceutical Industries Shares Retreat After FDA Rejection Letter

Teva Pharmaceutical Industries Ltd. shares fell 0.7% to $10.11 after hours Tuesday after the Food and Drug Administration sent a rejection...

2022-04-17 - FDA Rejection Cuts Off Teva Pharmaceutical Stock's Rally

The shares of Teva Pharmaceutical Industries Ltd (NYSE:TEVA) are down 3.3% at $9.84 this morning, following news that the U.S. Food and Drug...

2022-04-17 - Teva and MedinCell Receive Complete Response Letter for TV ...

PARSIPPANY, N.J. & TEL AVIV, Israel & PARIS--(BUSINESS WIRE)--Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd.

2021-10-27 - Teva Reports Third Quarter 2021 Financial Results - Form 8-K

Teva Reports Third Quarter 2021 Financial Results Revenues of $3.9 billion GAAP diluted EPS of $0.26 Non-GAAP diluted EPS of $0.59 Cash flow generated from operating activities of $529 million Free cash flow of $795 million Full year 2021 business outlook reaffirmed Net revenues of $16.0 ...

2021-07-28 - Teva Pharmaceutical Industries : Reports Second Quarter 2021 Financial Results (Form 8-K)

Teva Reports Second Quarter 2021 Financial Results Revenues of $3.9 billion GAAP diluted EPS of $0.19 Non-GAAP diluted EPS of $0.59 Cash flow generated from operating activities of $218 million Free cash flow of $625 million 2021 revenue outlook revised lower to reflect ongoing impact of C ...